肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

J Exp Med：浙大董辰方教授发现糖尿病药物对乳腺癌有积极作用

2017-03-13 MedSci MedSci原创

糖尿病药物乳腺癌作用
关注

自中国的一组医疗团队风险一种名为 AKR1B1 的代谢酶对乳腺癌的作用。研究表示，AKR1B1 可以通过积极的反馈回路促进基底细胞型乳腺癌的发展。研究报告发表于《实验医学》杂志中，具体指出了通过代谢酶的抑制剂治疗乳腺癌的方法。

自中国浙江大学董辰方教授团队风险一种名为 AKR1B1 的代谢酶对乳腺癌的作用。研究表示，AKR1B1 可以通过积极的反馈回路促进基底细胞型乳腺癌的发展。研究报告发表于《实验医学》杂志中，具体指出了通过代谢酶的抑制剂治疗乳腺癌的方法。


大约 15 - 20% 的乳腺癌是基底细胞型乳腺癌，其中包括三阴性乳腺癌，此类癌症易复发，也会转移到肺部和大脑。目前，还没有有效的治疗方法。

基底细胞型乳腺癌的侵略性就在于上皮间质转化的过程，癌细胞变得更加能动，并且获得使它们抵抗治疗，启动肿瘤在其他组织生长的干细胞性质。在此次研究中，科学家发现代谢酶 AKR1B1 的作用。

击败 ARK1B1 就可以抑制肿瘤的生长，除此之外，研究人员发现一种抑制 ARK1B1 的药物，名为依帕司他，这种药在日本被批准用来治疗由糖尿病引起的周围神经病变，使用它可以抑制基底细胞型乳腺癌的发展和转移。

研究人员总结称：“因为依帕司他是已经上市的药物，也没有什么严重的副作用，由于我们提供的证据，它有望成为治疗基底细胞型乳腺癌的临床药物。”

原始出处：

Wu X, Li X, Fu Q, Cao Q, Chen X, Wang M, Yu J, Long J, Yao J, Liu H, Wang D, Liao R, Dong C.　AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program.　J Exp Med. 2017 Mar 7. pii: jem.20160903. doi: 10.1084/jem.20160903.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1535976, encodeId=a3a315359e64f, content=<a href='/topic/show?id=67446550602' target=_blank style='color:#2F92EE;'>#浙大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65506, encryptionId=67446550602, topicName=浙大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42f112649926, createdName=pandamao2014, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584087, encodeId=4ff1158408e5b, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607289, encodeId=922a160e289ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179621, encodeId=fff21e962122, content=好好学习，涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Mon Mar 13 16:02:39 CST 2017, time=2017-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179559, encodeId=068e1e955964, content=期待临床研究结婚, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Mar 13 11:56:56 CST 2017, time=2017-03-13, status=1, ipAttribution=)]
    2017-03-15 pandamao2014

    #浙大#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1535976, encodeId=a3a315359e64f, content=<a href='/topic/show?id=67446550602' target=_blank style='color:#2F92EE;'>#浙大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65506, encryptionId=67446550602, topicName=浙大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42f112649926, createdName=pandamao2014, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584087, encodeId=4ff1158408e5b, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607289, encodeId=922a160e289ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179621, encodeId=fff21e962122, content=好好学习，涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Mon Mar 13 16:02:39 CST 2017, time=2017-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179559, encodeId=068e1e955964, content=期待临床研究结婚, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Mar 13 11:56:56 CST 2017, time=2017-03-13, status=1, ipAttribution=)]
    2017-03-15 minhuang75_72521589

    #糖尿病药物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1535976, encodeId=a3a315359e64f, content=<a href='/topic/show?id=67446550602' target=_blank style='color:#2F92EE;'>#浙大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65506, encryptionId=67446550602, topicName=浙大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42f112649926, createdName=pandamao2014, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584087, encodeId=4ff1158408e5b, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607289, encodeId=922a160e289ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179621, encodeId=fff21e962122, content=好好学习，涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Mon Mar 13 16:02:39 CST 2017, time=2017-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179559, encodeId=068e1e955964, content=期待临床研究结婚, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Mar 13 11:56:56 CST 2017, time=2017-03-13, status=1, ipAttribution=)]
    2017-03-15 ms3994565386320060

    #Med#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1535976, encodeId=a3a315359e64f, content=<a href='/topic/show?id=67446550602' target=_blank style='color:#2F92EE;'>#浙大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65506, encryptionId=67446550602, topicName=浙大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42f112649926, createdName=pandamao2014, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584087, encodeId=4ff1158408e5b, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607289, encodeId=922a160e289ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179621, encodeId=fff21e962122, content=好好学习，涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Mon Mar 13 16:02:39 CST 2017, time=2017-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179559, encodeId=068e1e955964, content=期待临床研究结婚, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Mar 13 11:56:56 CST 2017, time=2017-03-13, status=1, ipAttribution=)]
    2017-03-13 shaosai

    好好学习，涨知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1535976, encodeId=a3a315359e64f, content=<a href='/topic/show?id=67446550602' target=_blank style='color:#2F92EE;'>#浙大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65506, encryptionId=67446550602, topicName=浙大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42f112649926, createdName=pandamao2014, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584087, encodeId=4ff1158408e5b, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607289, encodeId=922a160e289ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 15 00:17:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179621, encodeId=fff21e962122, content=好好学习，涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Mon Mar 13 16:02:39 CST 2017, time=2017-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179559, encodeId=068e1e955964, content=期待临床研究结婚, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Mar 13 11:56:56 CST 2017, time=2017-03-13, status=1, ipAttribution=)]
    2017-03-13 cqykthl

    期待临床研究结婚

    0

相关资讯

FDA顾问小组支持批准吸入型糖尿病药物Afrezza

4月1日，美国FDA顾问小组推荐批准MannKind公司的吸入型糖尿病药物Afrezza，称这款药物可能会帮助患者，特别是那些对胰岛素注射针头有恐惧心理的患者。FDA顾问小组表示，虽然Afrezza对1型糖尿病成人患者没有表现出收益，但它对更常见的2型糖尿病却是明显安全有效的。 总之，顾问小组以13比1的投票结果推荐批准这款药物用于1型糖尿病患者，一致投票支持其用于2型糖尿病患者，并补充称，这款药

糖尿病药物吡格列酮遭90亿罚单 波及国内30余家制药公司

8日晚间，因被指控隐瞒旗下糖尿病药物艾可拓（Actos）相关致癌风险，美国联邦法院陪审团对日本最大药商武田制药和美国礼来制药分别处以60亿美元和30亿美元罚款。 这一判罚也成为美国制药业历史上领到的最大一笔罚单。 资料显示，1999年进入美国市场的艾可拓（化学通用名：吡格列酮）是日本最大制药公司武田制药用于糖尿病治疗的口服用药，在多个国家，武田制药先后与辉瑞等、礼来其他制药公司采取联合推广模式

GLP-1类糖尿病药物的胰腺炎风险引起监管机构重视

两个月前，发表在《美国医学会杂志》上的一篇有关一些重磅糖尿病药物与癌症风险相关的研究论文引发出一些新的问题。一个月之前，FDA声称正在就该项研究中提及的两款糖尿病药物（默沙东的西他列汀及百时美施贵宝和阿斯利康的艾塞那肽）以及包括诺和诺德重磅炸弹级药物利拉鲁肽在内的其它药物进行审查。目前，如Pharmalot报道，一支安全监管组织对FDA收集的不良反应数据进行了分析，发现与早先的糖尿病治疗药物相比，

新研究发现：两种糖尿病药物 或有助治疗痴呆

英国一项最新研究发现，两种现有的糖尿病治疗药物能保护患痴呆症动物的脑部神经，防止病情恶化。这一研究有望为痴呆症治疗提供新思路。 早老性痴呆症是最常见的痴呆症类型，目前尚无有效疗法及针对性药物。患者脑部神经受损，会出现记忆、语言和认知障碍等症状。 英国兰开斯特大学的研究人员在新一期英国《神经药理学》杂志上报告说，他们在动物实验中，给早老性痴呆症患病早期的实验鼠服用两种糖尿病治疗药物，结果发现

降糖药吡格列酮或面临限制使用

　　据了解，8月4日，美国食品和药物管理局(FDA)官网称，吡格列酮使用一年多以上可能增加罹患膀胱癌的风险。而据道琼斯通讯社消息，法国与德国已于7月上旬暂停了这款药物的临床使用。在中国，国家食品药品监督管理局(SFDA)还没有做出相关通知。 　　TZD类糖尿病药物或将“全军覆没” 　　吡格列酮，是很多用于治疗2型糖尿病的药物的重要成分。在罗格列酮(以文迪雅为代表)被严格限制使用之后，吡格列酮本

泰格医药与默沙东拟达成1.49亿元糖尿病药物临床试验合同

8月31日，本土CRO公司泰格医药发布公告称，该公司与默沙东(中国)投资有限公司于31日签署捷诺维(西格列汀)上市后二型糖尿病临床试验服务合同的第一期工作订单。双方合作的整体合同金额预计为1.49亿元。由于项目需要立即开展，双方达成一致，于31日签署了第一期工作订单，第一期订单的总金额为2127.43万元。 公告称，由于该合同总金额较大，双方公司将花费较长时间商讨合同细节，整体合同签署日期待定。